Myrtle Potter Net Worth

The estimated Net Worth of Myrtle S Potter is at least $848 Thousand dollars as of 15 August 2024. Ms. Potter owns over 68 units of Myovant Sciences Ltd stock worth over $362,827 and over the last 21 years she sold MYOV stock worth over $141,615. In addition, she makes $343,529 as Chairman of the Board at Myovant Sciences Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Potter MYOV stock SEC Form 4 insiders trading

Myrtle has made over 24 trades of the Myovant Sciences Ltd stock since 2015, according to the Form 4 filled with the SEC. Most recently she exercised 68 units of MYOV stock worth $1,835 on 15 August 2024.

The largest trade she's ever made was selling 28,189 units of Myovant Sciences Ltd stock on 3 October 2017 worth over $58,915. On average, Myrtle trades about 719 units every 47 days since 2004. As of 15 August 2024 she still owns at least 13,448 units of Myovant Sciences Ltd stock.

You can see the complete history of Ms. Potter stock trades at the bottom of the page.

Myrtle Potter biography

Myrtle Stephens Potter is Chairman of the Board of the Company. Ms. Potter has served as a member of the Board since September 2018 and has served as the Chairman of the Board since November 2018. Ms. Potter has served as Vant Operating Chair of Roivant Sciences, Inc., a wholly-owned subsidiary of RSL, since July 2018. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences consulting firm, in September 2005, and served as the Chief Executive Officer until June 2018. From August 2009 until December 2014, Ms. Potter served as Founder and Chief Executive Officer of Myrtle Potter Media, Inc., a consumer healthcare company. From 2000 to 2004, Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005, she served as the President, Commercial Operations and Executive Vice President of Genentech. Prior to that, Ms. Potter held various positions, including President, Cardiovascular/Metabolics at Bristol-Myers Squibb and a vice president at Merck & Co. Ms. Potter currently serves on the boards of directors of Axovant Gene Therapies Ltd., Urovant Sciences Ltd., Arbutus Biopharma Corporation and Axsome Therapeutics, Inc., each a pharmaceutical company, Liberty Mutual Holding Company Inc., a diversified global insurance company, and a number of privately held companies. Ms. Potter previously served on the boards of directors of INSMED Incorporated, a biopharmaceutical company, from December 2014 to November 2018, Rite Aid Corporation, a leading drugstore chain, from December 2013 to October 2018, Everyday Health, Inc., a leading provider of digital health and wellness solutions, from October 2010 until its acquisition in December 2016, and Amazon.com, Inc., a leading e-commerce company, from 2004 to 2009. Ms. Potter earned her B.A. from the University of Chicago.

What is the salary of Myrtle Potter?

As the Chairman of the Board of Myovant Sciences Ltd, the total compensation of Myrtle Potter at Myovant Sciences Ltd is $343,529. There are 7 executives at Myovant Sciences Ltd getting paid more, with Lynn Seely having the highest compensation of $6,222,670.

How old is Myrtle Potter?

Myrtle Potter is 61, she's been the Chairman of the Board of Myovant Sciences Ltd since 2018. There are 3 older and 9 younger executives at Myovant Sciences Ltd. The oldest executive at Myovant Sciences Ltd is Kathleen Sebelius, 72, who is the Lead Independent Director.

What's Myrtle Potter's mailing address?

Myrtle's mailing address filed with the SEC is 3100, Hanover Street, Palo Alto, Santa Clara County, California, 94306, United States.

Insiders trading at Myovant Sciences Ltd

Over the last 8 years, insiders at Myovant Sciences Ltd have traded over $5,780,890 worth of Myovant Sciences Ltd stock and bought 96,585,963 units worth $2,001,605,371 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ..., and Andrew Lo. On average, Myovant Sciences Ltd executives and independent directors trade stock every 15 days with the average trade being worth of $25,106,967. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 10 March 2023, trading 51,599,200 units of MYOV stock currently worth $1,393,178,400.

What does Myovant Sciences Ltd do?

Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.

Complete history of Ms. Potter stock trades at Amazon.com, Arbutus Biopharma Corp, Axsome Therapeutics Inc, Insmed Inc, Rite Aid, Myovant Sciences Ltd, Urovant Sciences Ltd, Guardant Health Inc, Immunovant Inc, and Axovant Gene Therapies

Myovant Sciences Ltd executives and stock owners

Myovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Lynn Seely,
  Principal Executive Officer, Director
• Matthew Lang,
  General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc.
• Frank Karbe,
  Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc.
• Juan Camilo Arjona Ferreira,
  Chief Commercial Officer - Myovant Sciences, Inc
• David C. Marek,
  CEO & Director
• Matthew Lang J.D.,
  Gen. Counsel & Corp. Sec.
• Kathleen Sebelius,
  Lead Independent Director
• Myrtle Potter,
  Chairman of the Board
• Mark Guinan,
  Independent Director
• Terrie Curran,
  Independent Director
• Adele Gulfo,
  Director, Interim Chief Commercial Officer
• Hiroshi Nomura,
  Director
• Dr. Andria Langenberg M.D.,
  Head of Drug Safety & Pharmacovigilance
• Dr. Teresa Perney Ph.D.,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Juan Camilo Arjona Ferreira M.D.,
  Chief Medical Officer
• Bryan Selby,
  Sr. VP of Product Devel.
• Julie Tran MBA, MSHR,
  Sr. VP of HR
• Albert Liao,
  Director of Corp. Communications
• Ryan Crowe,
  VP of Investor Relations
• Uneek Mehra,
  Chief Financial & Bus. Officer
• Kim Sablich,
  Chief Commercial Officer
• Uneek Mehra,
  Principal Financial Officer
• David C Marek,
  Principal Executive Officer
• Wayne S De Veydt,
  Director
• Mark Altmeyer,
  Director
• Pharmaceuticals Internation...,
  10% owner
• Global Investors Lp Viking ...,
  
• Holdings Ltd.Dexcel Pharma ...,
  
• Global Performance Llc Viki...,
  
• Investments (Uk) Ltd Soft B...,
  
• Sciences Ltd. Roivant,
  10% owner
• Patrick Machado,
  
• Associates Gp Llcqvt Fund V...,
  
• Global Performance Llc Viki...,
  
• Pharmaceuticals Internation...,
  
• Frank Torti,
  Director
• Chemical Co., Ltd.Sumitomo ...,
  
• Lauren Merendino,
  Chief Commercial Officer
• Nancy Valente,
  Director